Interpretation of the Kidney Disease: Improving Global Outcomes Guidelines for Iron Therapy: Commentary and Emerging Evidence

Overview

Journal Clin Kidney J

Publisher Oxford University Press

Specialty Nephrology

Date 2017 Dec 12

PMID 29225817

Citations 4

Authors

Jeffrey S Berns

Affiliations

Soon will be listed here.

Abstract

The 'Kidney Disease: Improving Global Outcomes' (KDIGO) Clinical Practice Guideline for Anaemia in Chronic Kidney Disease includes detailed recommendations for the use of iron therapy in a variety of clinical circumstances. However, the evidence base regarding the use of iron therapy in patients with chronic kidney disease was relatively incomplete at the time the guideline was developed. As a result, there has been significant debate as to the appropriate use of iron therapy in this population. In this article, the KDIGO guidelines are discussed in the context of recently published commentary pieces and additional research to provide a richer context in which to interpret and understand the guidelines.

Citing Articles

Association Between the Polymorphism of Angiotensin-Converting Enzyme Gene and Interleukin-1 Beta Gene and the Response to Erythropoietin Therapy in Dialysis Patients with Anemia.

Dzekova-Vidimliski P, Eftimovska-Otovikj N, Nikolov I, Selim G, Rambabova-Bushljetik I, Pushevski V Balkan J Med Genet. 2024; 26(2):27-34.

PMID: 38482261 PMC: 10932603. DOI: 10.2478/bjmg-2023-0022.

Erythropoietin Resistance Development in Hemodialysis Patients: The Role of Oxidative Stress.

Jovic J, Antic S, Nikolic T, Andric K, Petrovic D, Bolevich S Oxid Med Cell Longev. 2022; 2022:9598211.

PMID: 35464768 PMC: 9023176. DOI: 10.1155/2022/9598211.

Iatrogenic Iron Overload in a Patient With Chronic Kidney Disease: Is There a Correlation Between Serum Ferritin and Liver Iron Concentration Determined by MRI T2*?.

Ali M, Okar L, Iqbal P, Yassin M Cureus. 2020; 12(6):e8914.

PMID: 32742880 PMC: 7389957. DOI: 10.7759/cureus.8914.

Evaluation of iron stores in hemodialysis patients on maintenance ferric Carboxymaltose dosing.

Diebold M, Kistler A BMC Nephrol. 2019; 20(1):76.

PMID: 30823916 PMC: 6397449. DOI: 10.1186/s12882-019-1263-8.

References

Besarab A, Kaiser J, Frinak S . A study of parenteral iron regimens in hemodialysis patients. Am J Kidney Dis. 1999; 34(1):21-8. DOI: 10.1016/s0272-6386(99)70103-4. View

Pietrangelo A, Montosi G, Totaro A, Garuti C, Conte D, Cassanelli S . Hereditary hemochromatosis in adults without pathogenic mutations in the hemochromatosis gene. N Engl J Med. 1999; 341(10):725-32. DOI: 10.1056/NEJM199909023411003. View

Sunder-Plassmann G, Patruta S, Horl W . Pathobiology of the role of iron in infection. Am J Kidney Dis. 1999; 34(4 Suppl 2):S25-9. DOI: 10.1053/AJKD034s00025. View

. IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. Am J Kidney Dis. 2001; 37(1 Suppl 1):S182-238. DOI: 10.1016/s0272-6386(01)70008-x. View

Himmelfarb J, Stenvinkel P, Ikizler T, Hakim R . The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002; 62(5):1524-38. DOI: 10.1046/j.1523-1755.2002.00600.x. View

Tovbin D, Mazor D, Vorobiov M, Chaimovitz C, Meyerstein N . Induction of protein oxidation by intravenous iron in hemodialysis patients: role of inflammation. Am J Kidney Dis. 2002; 40(5):1005-12. DOI: 10.1053/ajkd.2002.36334. View

Canavese C, Bergamo D, Ciccone G, Longo F, Fop F, Thea A . Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int. 2004; 65(3):1091-8. DOI: 10.1111/j.1523-1755.2004.00480.x. View

Gandon Y, Olivie D, Guyader D, Aube C, Oberti F, Sebille V . Non-invasive assessment of hepatic iron stores by MRI. Lancet. 2004; 363(9406):357-62. DOI: 10.1016/S0140-6736(04)15436-6. View

St Pierre T, Clark P, Chua-anusorn W, Fleming A, Jeffrey G, Olynyk J . Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood. 2004; 105(2):855-61. DOI: 10.1182/blood-2004-01-0177. View

10.

Van Wyck D . Labile iron: manifestations and clinical implications. J Am Soc Nephrol. 2004; 15 Suppl 2:S107-11. DOI: 10.1097/01.ASN.0000143816.04446.4C. View

11.

Aronoff G . Safety of intravenous iron in clinical practice: implications for anemia management protocols. J Am Soc Nephrol. 2004; 15 Suppl 2:S99-106. DOI: 10.1097/01.ASN.0000143815.15433.87. View

12.

Eschbach J . Iron requirements in erythropoietin therapy. Best Pract Res Clin Haematol. 2005; 18(2):347-61. DOI: 10.1016/j.beha.2004.09.005. View

13.

Locatelli F, Andrulli S, Memoli B, Maffei C, Del Vecchio L, Aterini S . Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant. 2005; 21(4):991-8. DOI: 10.1093/ndt/gfk011. View

14.

Rossert J, Gassmann-Mayer C, Frei D, McClellan W . Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients. Nephrol Dial Transplant. 2007; 22(3):794-800. DOI: 10.1093/ndt/gfl716. View

15.

Coyne D, Kapoian T, Suki W, Singh A, Moran J, Dahl N . Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 2007; 18(3):975-84. DOI: 10.1681/ASN.2006091034. View

16.

Pai A, Boyd A, McQuade C, Harford A, Norenberg J, Zager P . Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis. Pharmacotherapy. 2007; 27(3):343-50. DOI: 10.1592/phco.27.3.343. View

17.

Kapoian T, OMara N, Singh A, Moran J, Rizkala A, Geronemus R . Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol. 2008; 19(2):372-9. PMC: 2396742. DOI: 10.1681/ASN.2007050606. View

18.

Kuo K, Hung S, Wei Y, Tarng D . Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients. J Am Soc Nephrol. 2008; 19(9):1817-26. PMC: 2518435. DOI: 10.1681/ASN.2007101084. View

19.

Spinowitz B, Kausz A, Baptista J, Noble S, Sothinathan R, Bernardo M . Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol. 2008; 19(8):1599-605. PMC: 2488268. DOI: 10.1681/ASN.2007101156. View

20.

Weinberg E . Iron availability and infection. Biochim Biophys Acta. 2008; 1790(7):600-5. DOI: 10.1016/j.bbagen.2008.07.002. View